During an FDA inspection of Jagsonpal Pharmaceuticals Limited in Gurugram, Haryana, India from 20 March to 3 April 2024, serious GMP violations were identified, leading to an import alert. Key deficiencies included:
The FDA has recommended a comprehensive quality system review and suggests hiring an independent GMP consultant.
25-04-2025